nach oben

Journal of Neuro-Oncology

Erschienen in:

22.11.2017 | Laboratory Investigation

Bioinformatic analysis of gene expression and methylation regulation in glioblastoma

verfasst von: Wen Wang, Zheng Zhao, Fan Wu, Haoyuan Wang, Jiangfei Wang, Qing Lan, Jizong Zhao

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Different gene expression and methylation profiles are identified in glioblastoma (GBM). To screen the differentially expressed genes affected by DNA methylation modification and further investigate their prognostic values for GBMs. We included The Cancer Genome Atlas (TCGA) RNA sequencing (676) and DNA methylation (Illumina Human Methylation 450K; 657) databases to detect the gene expression and methylation profiles. Chinese Glioma Genome Atlas (CGGA) RNA sequencing database and TCGA DNA methylation (Illumina Human Methylation 27K; 283) was included for validation. Gene expression and DNA methylation statues were identified using principal components analysis (PCA). A total of 3365 differentially expressed genes were identified. Among them, 2940 genes showed low methylation and high expression, while 425 genes showed high methylation and low expression in GBMs. An eight-gene (C9orf64, OSMR, MDK, MARVELD1, PTRF, MYD88, BIRC3, RPP25) signature was established to divide GBM patients into two groups based on the cut-off point (27.24). The high risk group had shorter overall survival (OS) than low risk group (median OS 15.77 vs. 10.61 months; P = 0.0002). Moreover, the different clinical and molecular features were shown between two groups. These findings could be validated in additional datasets. The differentially expressed genes affected by DNA methylation modification were detected. Our results showed that the eight-gene signature has independently prognostic value for GBM patients.

Nur mit Berechtigung zugänglich

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. https://doi.org/10.1056/NEJMoa043330 CrossRefPubMed

Yang P, Zhang W, Wang Y, Peng X, Chen B, Qiu X, Li G, Li S, Wu C, Yao K, Li W, Yan W, Li J, You Y, Chen CC, Jiang T (2015) IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. Oncotarget 6(38):40896–40906. https://doi.org/10.18632/oncotarget.5683 CrossRefPubMedPubMedCentral

Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116(6):597–602. https://doi.org/10.1007/s00401-008-0455-2 CrossRefPubMed

Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812. https://doi.org/10.1126/science.1164382 CrossRefPubMedPubMedCentral

Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118(4):469–474. https://doi.org/10.1007/s00401-009-0561-9 CrossRefPubMed

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773. https://doi.org/10.1056/NEJMoa0808710 CrossRefPubMedPubMedCentral

Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343(19):1350–1354. https://doi.org/10.1056/NEJM200011093431901 CrossRefPubMed

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003. https://doi.org/10.1056/NEJMoa043331 CrossRefPubMed

Karsy M, Neil JA, Guan J, Mahan MA, Colman H, Jensen RL (2015) A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg Focus 38(3):E4. https://doi.org/10.3171/2015.1.focus14755 CrossRefPubMed

10.

Chinot OL, Barrie M, Fuentes S, Eudes N, Lancelot S, Metellus P, Muracciole X, Braguer D, Ouafik L, Martin PM, Dufour H, Figarella-Branger D (2007) Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 25(12):1470–1475. https://doi.org/10.1200/JCO.2006.07.4807 CrossRefPubMed

11.

Eoli M, Menghi F, Bruzzone MG, De Simone T, Valletta L, Pollo B, Bissola L, Silvani A, Bianchessi D, D’Incerti L, Filippini G, Broggi G, Boiardi A, Finocchiaro G (2007) Methylation of O-6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res 13(9):2606–2613. https://doi.org/10.1158/1078-0432.CCR-06-2184 CrossRefPubMed

12.

Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR (2008) Correlation of O-6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26(25):4189–4199. https://doi.org/10.1200/JCO.2007.11.5964 CrossRefPubMed

13.

Verbeek B, Southgate TD, Gilham DE, Margison GP (2008) O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy. Br Med Bull 85:17–33. https://doi.org/10.1093/bmb/ldm036 CrossRefPubMed

14.

LeBlanc VG, Marra MA (2016) DNA methylation in adult diffuse gliomas. Brief Funct Genom 15(6):491–500. https://doi.org/10.1093/bfgp/elw019

15.

Cheng W, Li M, Cai J, Wang K, Zhang C, Bao Z, Liu Y, Wu A (2015) HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation. J Neurooncol 122(2):303–312. https://doi.org/10.1007/s11060-014-1709-6 CrossRefPubMedPubMedCentral

16.

Bao ZS, Li MY, Wang JY, Zhang CB, Wang HJ, Yan W, Liu YW, Zhang W, Chen L, Jiang T (2014) Prognostic value of a nine-gene signature in glioma patients based on mRNA expression profiling. CNS Neurosci Therapeut 20(2):112–118. https://doi.org/10.1111/cns.12171 CrossRef

17.

Zhang CB, Zhu P, Yang P, Cai JQ, Wang ZL, Li QB, Bao ZS, Zhang W, Jiang T (2015) Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling. Oncotarget 6(34):36643–36651. https://doi.org/10.18632/oncotarget.5421 PubMedPubMedCentral

18.

Heagerty PJ, Lumley T, Pepe MS (2000) Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56(2):337–344CrossRefPubMed

19.

Wang W, Zhang L, Wang Z, Yang F, Wang H, Liang T, Wu F, Lan Q, Wang J, Zhao J (2016) A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma. Oncotarget 7(43):69991–69999. https://doi.org/10.18632/oncotarget.11726 PubMedPubMedCentral

20.

Wang W, Yang F, Zhang L, Chen J, Zhao Z, Wang H, Wu F, Liang T, Yan X, Li J, Lan Q, Wang J, Zhao J (2016) LncRNA profile study reveals four-lncRNA signature associated with the prognosis of patients with anaplastic gliomas. Oncotarget 7(47):77225–77236. https://doi.org/10.18632/oncotarget.12624 PubMedPubMedCentral

21.

Winder DM, Chattopadhyay A, Muralidhar B, Bauer J, English WR, Zhang X, Karagavriilidou K, Roberts I, Pett MR, Murphy G, Coleman N (2011) Overexpression of the oncostatin M receptor in cervical squamous cell carcinoma cells is associated with a pro-angiogenic phenotype and increased cell motility and invasiveness. J Pathol 225(3):448–462. https://doi.org/10.1002/path.2968 CrossRefPubMed

22.

Kucia-Tran JA, Tulkki V, Smith S, Scarpini CG, Hughes K, Araujo AM, Yan KY, Botthof J, Perez-Gomez E, Quintanilla M, Cuschieri K, Caffarel MM, Coleman N (2016) Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival. Br J Cancer 115(2):212–222. https://doi.org/10.1038/bjc.2016.199 CrossRefPubMedPubMedCentral

23.

Natesh K, Bhosale D, Desai A, Chandrika G, Pujari R, Jagtap J, Chugh A, Ranade D, Shastry P (2015) Oncostatin-M differentially regulates mesenchymal and proneural signature genes in gliomas via STAT3 signaling. Neoplasia 17(2):225–237. https://doi.org/10.1016/j.neo.2015.01.001 CrossRefPubMedPubMedCentral

24.

Hibi K, Goto T, Sakuraba K, Shirahata A, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y (2011) Methylation of OSMR gene is frequently observed in non-invasive colorectal cancer. Anticancer Res 31(4):1293–1295PubMed

25.

Kim MS, Louwagie J, Carvalho B, Terhaar Sive Droste JS, Park HL, Chae YK, Yamashita K, Liu J, Ostrow KL, Ling S, Guerrero-Preston R, Demokan S, Yalniz Z, Dalay N, Meijer GA, Van Criekinge W, Sidransky D (2009) Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer. PLoS ONE 4(8):e6555. https://doi.org/10.1371/journal.pone.0006555 CrossRefPubMedPubMedCentral

26.

Yuan K, Chen Z, Li W, Gao CE, Li G, Guo G, Yang Y, Ai Y, Wu L, Zhang M (2015) MDK protein overexpression correlates with the malignant status and prognosis of non-small cell lung cancer. Arch Med Res 46(8):635–641. https://doi.org/10.1016/j.arcmed.2015.11.006 CrossRefPubMed

27.

Li F, Tian P, Zhang J, Kou C (2015) The clinical and prognostic significance of midkine in breast cancer patients. Tumour Biol 36(12):9789–9794. https://doi.org/10.1007/s13277-015-3710-x CrossRefPubMed

28.

Rawnaq T, Dietrich L, Wolters-Eisfeld G, Uzunoglu FG, Vashist YK, Bachmann K, Simon R, Izbicki JR, Bockhorn M, Gungor C (2014) The multifunctional growth factor midkine promotes proliferation and migration in pancreatic cancer. Mol Cancer Res 12(5):670–680. https://doi.org/10.1158/1541-7786.MCR-13-0467 CrossRefPubMed

29.

Shao H, Yu X, Wang C, Wang Q, Guan H (2014) Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer. Endocrine 46(2):285–291. https://doi.org/10.1007/s12020-013-0068-y CrossRefPubMed

30.

Tomizawa M, Yu L, Wada A, Tamaoki T, Kadomatsu K, Muramatsu T, Matsubara S, Watanabe K, Ebara M, Saisho H, Sakiyama S, Tagawa M (2003) A promoter region of the midkine gene that is frequently expressed in human hepatocellular carcinoma can activate a suicide gene as effectively as the alpha-fetoprotein promoter. Br J Cancer 89(6):1086–1090. https://doi.org/10.1038/sj.bjc.6601246 CrossRefPubMedPubMedCentral

31.

Jia M, Zhao HZ, Cheng YP, Luo ZB, Zhang JY, Li SS, Xu XJ, Tang YM (2016) High expression of Midkine (MK) indicates poor prognosis in childhood acute lymphoblastic leukemia. Hematology 21(2):69–77. https://doi.org/10.1179/1607845415Y.0000000050 PubMed

32.

Cortese R, Hartmann O, Berlin K, Eckhardt F (2008) Correlative gene expression and DNA methylation profiling in lung development nominate new biomarkers in lung cancer. Int J Biochem Cell Biol 40(8):1494–1508. https://doi.org/10.1016/j.biocel.2007.11.018 CrossRefPubMed

33.

Wang S, Li Y, Han F, Hu J, Yue L, Yu Y, Zhang Y, He J, Zheng H, Shi S, Fu X, Wu H (2009) Identification and characterization of MARVELD1, a novel nuclear protein that is down-regulated in multiple cancers and silenced by DNA methylation. Cancer Lett 282(1):77–86. https://doi.org/10.1016/j.canlet.2009.03.008 CrossRefPubMed

34.

Shi M, Wang S, Yao Y, Li Y, Zhang H, Han F, Nie H, Su J, Wang Z, Yue L, Cao J, Li Y (2014) Biological and clinical significance of epigenetic silencing of MARVELD1 gene in lung cancer. Sci Rep 4:7545. https://doi.org/10.1038/srep07545 CrossRefPubMedPubMedCentral

35.

Cai J, Zhang C, Zhang W, Wang G, Yao K, Wang Z, Li G, Qian Z, Li Y, Jiang T, Jiang C (2016) ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors. Oncoscience 3(7–8):258–265. https://doi.org/10.18632/oncoscience.317 PubMedPubMedCentral

36.

Huertas-Martinez J, Court F, Rello-Varona S, Herrero-Martin D, Almacellas-Rabaiget O, Sainz-Jaspeado M, Garcia-Monclus S, Lagares-Tena L, Buj R, Hontecillas-Prieto L, Sastre A, Azorin D, Sanjuan X, Lopez-Alemany R, Moran S, Roma J, Gallego S, Mora J, Garcia Del Muro X, Giangrande PH, Peinado MA, Alonso J, de Alava E, Monk D, Esteller M, Tirado OM (2017) DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1. Cancer Lett 386:196–207. https://doi.org/10.1016/j.canlet.2016.11.020 CrossRefPubMed

37.

Li Z, Chen J, Chan KW, Qiao L, Wong BC (2011) A possible role of cIAP2 in Helicobacter pylori-associated gastric cancer. Cancer Lett 313(2):192–200. https://doi.org/10.1016/j.canlet.2011.09.007 CrossRefPubMed

38.

Wang D, Berglund A, Kenchappa RS, Forsyth PA, Mule JJ, Etame AB (2016) BIRC3 is a novel driver of therapeutic resistance in glioblastoma. Sci Rep 6:21710. https://doi.org/10.1038/srep21710 CrossRefPubMedPubMedCentral

39.

Chen YK, Huse SS, Lin LM (2011) Expression of inhibitor of apoptosis family proteins in human oral squamous cell carcinogenesis. Head Neck 33(7):985–998. https://doi.org/10.1002/hed.21582 CrossRefPubMed

40.

Ohba S, Hirose Y (2016) Current and future drug treatments for glioblastomas. Curr Med Chem 23(38):4309–4316CrossRefPubMed

Titel: Bioinformatic analysis of gene expression and methylation regulation in glioblastoma
verfasst von: Wen Wang
Zheng Zhao
Fan Wu
Haoyuan Wang
Jiangfei Wang
Qing Lan
Jizong Zhao
Publikationsdatum: 22.11.2017
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2018
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2688-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Bioinformatic analysis of gene expression and methylation regulation in glioblastoma

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

18F-FDG PET/CT in primary brain lymphoma

P21Waf1/Cip1 and p27Kip1 are correlated with the development and invasion of prolactinoma

New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model

Spinal ependymomas in NF2: a surgical disease?

Clinical features, surgical management, and prognostic factors of secretory meningiomas: a single-center case series of 149 patients

CK4, CK6, cyclin D1, p16(INK4a) and EGFR expression in glioblastoma with a primitive neuronal component

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie